Publications en collaboration avec des chercheurs de Masaryk Memorial Cancer Institute (8)

2023

  1. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

    European Journal of Cancer, Vol. 184, pp. 48-59

2022

  1. Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial

    Breast Cancer Research and Treatment, Vol. 193, Núm. 1, pp. 95-103

2021

  1. Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

    Annals of Oncology

  2. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

    Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Overall survival with ribociclib plus fulvestrant in advanced breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524

2016

  1. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 17, Núm. 3, pp. 367-377

2009

  1. A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer

    Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 6, pp. 1139-1148